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ASTHMA—Clinical Outcomes Studies
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EPIDEMIOLOGY OF NASAL POLYPS AND ITS
RELATIONSHIP TO ASTHMA
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Serrano E5,Abdelkader EH3
1Hôpital Jean Bernard, Nancy, France; 2Faculté de médecine
Xavier Bichat, Paris, France; 3GSK, Marly le roi, France; 4Hôpital
central de Nancy, Nancy, France; 5Hôpital de Rangueil,
Toulouse, France
OBJECTIVES: To investigate the prevalence of nasal
polyposis (NP) in the French population of adults above
17 years old and the typology of these patients in com-
parison to a control group. METHODS: A total of
10,033 individuals of both sexes were interviewed face to
face with a validated speciﬁc questionnaire. A computer
assisted personal interviewing system (CAPI) allowed
thanks to an algorithm to separate on the spot the indi-
viduals with nasal polyps from the ones without. The
individuals with a positive diagnosis of NP were submit-
ted to a detailed questionnaire, which analysed the man-
agement of these patients. A control group of 502
individuals without NP was obtained by an adjustment
by age and sex to the NP group. RESULTS: A total of
212 NP individuals were identiﬁed (prevalence of 2.11%)
with no difference between sexes and a mean age of 49.4
years. The prevalence of NP tended to increase with age.
Frequent complaints were reported by the NP individu-
als: 30.8% of a blocked nose, 18.7% of a change of the
voice, 28.9% of anosmia (moderate and severe in around
50% of the cases), 11.6 % of loss of taste, but only 6.9%
of a feeling of discomfort in the face. The mean duration
of nasal symptoms was 22.4 years and 70% of patients
have seen a doctor for these problems. Asthma was
reported by 26.1% of the NP population and by 6% of
the control population (p < 0.0001). In the NP popula-
tion the intensity of the asthma was rated as moderate by
27.4% and severe by 36.8% of the patients. CONCLU-
SIONS: The prevalence of NP found in this large popu-
lation is around 2.1%. It shows that NP patients suffer
frequently from anosmia, ageusia and asthma.
ASTHMA—Cost Studies
PRP2
HELIOX IN THE TREATMENT OF STATUS
ASTHMATICUS IN THE ICU: A COST-
EFFECTIVENESS ANALYSIS
tano B1, Hoffmann S2, Pathak D2
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OBJECTIVE: Treatment of status asthmaticus in the 
ICU is evolving. Standard therapy consists of frequent
Albuterol and Atrovent Nebulizers in addition to oxygen
and corticosteroids. Most recently some clinicians have
used Heliox in addition to standard therapy. This study
focuses on the cost-effectiveness of this add-on therapy
modality. METHODS: Decision modeling is used to eval-
uate the cost-effectiveness of treatment modalities for
status asthmaticus in the ICU. From 2001 to 2003, 210
patients were admitted to the Ohio State University
Medical Center Intensive Care Unit with severe asthma
exacerbation. Twenty of these patients received Heliox
plus standard therapy and 170 received standard therapy
alone. A 4 :1 matched case-control design is used to eval-
uate the effect of Heliox as adjuvant therapy in status
asthmaticus. All patients are drawn from the adult 
population. Cost is measured as Heliox cost, cost of 
standard medications such as Albuterol, Atrovent and
Corticosteroids in addition to ICU standard daily costs.
Effectiveness is measured as reduction in length of stay
for the two groups. RESULTS: Patients who used Heliox
had a decreased in length of stay compared to patients
who received standard care alone. On average a patient
who received Heliox therapy had a decrease of (2.5) days
in length of stay, which amounts to a cost saving of about
$10,000 in ICU costs. This cost saving does not include
indirect costs such as productivity-recovered secondary to
the reduced length of stay, and psychic costs such as
enjoyment of family. CONCLUSIONS: Heliox reduces
the length of hospital stay for status asthmaticus patients.
The cost/effectiveness ratio and the incremental cost/
effectiveness are optimal for these patients versus the non-
Heliox patients. Heliox is therefore cost saving and
should be contemplated for all asthma exacerbations.
PRP3
LOSSES IN PRODUCTIVITY DUE TO ASTHMA:
A POPULATION BASED ESTIMATE
Mychaskiw MA, Sankaranarayanan J
Purdue University, West Lafayette, IN, USA
OBJECTIVE: Asthma is a very common disease, affect-
ing approximately 5 percent of the adult population in
the United States. Beyond the U.S., the prevalence of
asthma has considerably increased among other industri-
alized countries, by more than 30% over the last 2
decades. Given this, it follows that the impact of asthma
on labor is a signiﬁcant concern and it becomes impor-
tant to assess asthma-related losses in productivity. The
objective of this study was to determine the indirect costs
due to asthma. METHODS: Retrospective analysis was
conducted of the 1999 Medical Expenditure Panel Survey.
The survey collected data from a nationally representa-
tive sample of 24,618 respondents and data from respon-
dents’ medical care and health insurance providers and
employers. Data elements used in this study included
medical conditions and employment information com-
prised of hourly earnings, hours worked, and disability
days. Asthma patients who incurred disability days
related to their condition were identiﬁed using Interna-
